癌症监测作为遗传性弥漫性胃癌预防性全胃切除术的替代方案:一项前瞻性队列研究
该前瞻性队列研究纳入270例无症状的种系CDH1变异携带者,评估内镜监测检测胃印戒细胞癌的有效性。截至数据截止日期共完成467次内镜,随访中位31.1个月,76例(63%)在两次以上监测内镜中检出印戒细胞癌,98例(36%)接受预防性全胃切除术,随访期间无进展期(III或IV期)癌症诊断。作者认为内镜监测是拒绝全胃切除术的CDH1变异携带者可接受的替代方案。
要点
- 270例CDH1变异携带者中,98例(36%)接受预防性全胃切除术。
- 120例接受两次以上监测内镜者中76例(63%)检出印戒细胞癌,其中74例为隐匿癌。
- 随访期间无进展期(III或IV期)癌症诊断,2例(1%)死亡。
核心结论
- 在该队列中,内镜癌症监测是拒绝全胃切除术的CDH1变异携带者可接受的替代手术方案。
- 作者认为,>T1a期肿瘤发生率低提示监测可能是CDH1变异携带者替代手术的合理选择。
研究设计与样本
- 前瞻性队列研究,纳入270例年龄≥2岁、携带致病或可能致病种系CDH1变异、在美国国立卫生研究院(Bethesda, MD, USA)接受内镜筛查和监测的无症状患者。
- 筛查定义为初次内镜,后续所有内镜均为监测,随访内镜间隔6至12个月。
- 主要目的是确定内镜监测检测胃印戒细胞癌的有效性。
主要发现
- 截至数据截止日期(2022年4月30日),270例患者共完成467次内镜,随访中位31.1个月(IQR 17.1-42.1)。
- 共获取38803份胃活检样本,其中1163份(3%)侵袭性印戒细胞癌阳性。
- 120例接受两次以上监测内镜的患者中76例(63%)检出印戒细胞癌,其中74例为隐匿癌,另2例出现局灶溃疡,分别对应pT3N0期癌。
- 98例(36%)接受预防性全胃切除术;内镜活检阴性后行全胃切除术的42例(42/98,43%)中39例(93%)检出多灶性IA期胃癌。
- 随访期间2例(1%)死亡,1例死于转移性小叶乳腺癌,1例死于基础脑血管病;无患者诊断为进展期(III或IV期)癌症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Loss of function variants in CDH1 are the most frequent cause of hereditary diffuse gastric cancer. Endoscopy is regarded as insufficient for early detection due to the infiltrative phenotype of diffuse-type cancers. Microscopic foci of invasive signet ring cells are pathognomonic of CDH1 and precede development of diffuse gastric cancer. We aimed to assess the safety and effectiveness of endoscopy for cancer interception in individuals with germline CDH1 variants, particularly in those who declined prophylactic total gastrectomy. METHODS: In this prospective cohort study, we included asymptomatic patients aged 2 years or older with pathogenic or likely pathogenic germline CDH1 variants who underwent endoscopic screening and surveillance at the National Institutes of Health (Bethesda, MD, USA) as part of a natural history study of hereditary gastric cancers (NCT03030404). Endoscopy was done with non-targeted biopsies and one or more targeted biopsy and assessment of focal lesions. Endoscopy findings, pathological data, personal and family cancer history, and demographics were recorded. Procedural morbidity, gastric cancer detection by endoscopy and gastrectomy, and cancer-specific events were assessed. Screening was defined as the initial endoscopy and all subsequent endoscopies were considered surveillance; follow-up endoscopy was at 6 to 12 months. The primary aim was to determine effectiveness of endoscopic surveillance for detection of gastric signet ring cell carcinoma. FINDINGS: Between Jan 25, 2017, and Dec 12, 2021, 270 patients (median age 46·6 years [IQR 36·5-59·8], 173 [64%] female participants, 97 [36%] male participants; 250 [93%] were non-Hispanic White, eight [3%] were multiracial, four [2%] were non-Hispanic Black, three [1%] were Hispanic, two [1%] were Asian, and one [<1%] was American Indian or Alaskan Native) with germline CDH1 variants were screened, in whom 467 endoscopies were done as of data cutoff (April 30, 2022). 213 (79%) of 270 patients had a family history of gastric cancer, and 176 (65%) reported a family history of breast cancer. Median follow-up was 31·1 months (IQR 17·1-42·1). 38 803 total gastric biopsy samples were obtained, of which 1163 (3%) were positive for invasive signet ring cell carcinoma. Signet ring cell carcinoma was detected in 76 (63%) of 120 patients who had two or more surveillance endoscopies, of whom 74 had occult cancer detected; the remaining two individuals developed focal ulcerations each corresponding to pT3N0 stage carcinoma. 98 (36%) of 270 patients proceeded to prophylactic total gastrectomy. Among patients who had a prophylactic total gastrectomy after an endoscopy with biopsy samples negative for cancer (42 [43%] of 98), multifocal stage IA gastric carcinoma was detected in 39 (93%). Two (1%) participants died during follow-up, one due to metastatic lobular breast cancer and the other due to underlying cerebrovascular disease, and no participants were diagnosed with advanced stage (III or IV) cancer during follow-up. INTERPRETATION: In our cohort, endoscopic cancer surveillance was an acceptable alternative to surgery in individuals with CDH1 variants who declined total gastrectomy. The low rate of incident tumours (>T1a) suggests that surveillance might be a rational alternative to surgery in individuals with CDH1 variants. FUNDING: Intramural Research Program, National Institutes of Health.
引用
- Asif B, Sarvestani AL, Gamble LA, et al. Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study. Lancet Oncol. 2023. PMID: 36990610. doi:10.1016/S1470-2045(23)00057-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。